“The IDEAL trial - a study protocol for a phase III randomized, double-blinded clinical trial assessing the ultra-short antibiotic prophylaxis of Isoniazid and Rifapentine in non-immunosuppressed patients with newly diagnosed latent tuberculosis”, PPCR, vol. 6, no. 1, pp. 9–14, May 2020, Accessed: Apr. 12, 2025. [Online]. Available: https://journal.ppcr.org/index.php/ppcrjournal/article/view/96